# Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

> **NCT04161352** · — · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Unresectable Stage III NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04161352
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-25
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161352, "Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04161352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*